Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial

• Published in: The Lancet (British edition) Vol. 397; no. 10291; pp. 2275 - 2283
• Main Authors: Visser, Margaretha M, Charleer, Sara, Fieuws, Steffen, De Block, Christophe, Hilbrands, Robert, Van Huffel, Liesbeth, Maes, Toon, Vanhaverbeke, Gerd, Dirinck, Eveline, Myngheer, Nele, Vercammen, Chris, Nobels, Frank, Keymeulen, Bart, Mathieu, Chantal, Gillard, Pieter
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 12.06.2021; Elsevier B.V; Elsevier Limited
• Subjects: Adult; Adults; Belgium; Blood Glucose - analysis; Blood Glucose Self-Monitoring; Blood sugar monitoring; Dextrose; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - drug therapy; Diabetes therapy; Female; Glucose; Glucose monitoring; Glycated Hemoglobin A - analysis; Glycosylated hemoglobin; Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemia - diagnosis; Hypoglycemic Agents - therapeutic use; Insulin; Insulin - therapeutic use; Insulin Infusion Systems; Male; Monitoring; Patient monitoring equipment; Prospective Studies; Quality of Life; Randomization; Real time; Sensors; Smartphones; Switching; Telemedicine; Type 1 diabetes; Belgium; United States > US
• ISSN: 0140-6736; 1474-547X; 1474-547X
• DOI: 10.1016/S0140-6736(21)00789-3

People with type 1 diabetes can continuously monitor their glucose levels on demand (intermittently scanned continuous glucose monitoring [isCGM]), or in real time (real-time continuous glucose monitoring [rtCGM]). However, it is unclear whether switching from isCGM to rtCGM with alert functionality offers additional benefits. Therefore, we did a trial comparing rtCGM and isCGM in adults with type 1 diabetes (ALERTT1). We did a prospective, double-arm, parallel-group, multicentre, randomised controlled trial in six hospitals in Belgium. Adults with type 1 diabetes who previously used isCGM were randomly assigned (1:1) to rtCGM (intervention) or isCGM (control). Randomisation was done centrally using minimisation dependent on study centre, age, gender, glycated haemoglobin (HbA1c), time in range (sensor glucose 3·9–10·0 mmol/L), insulin administration method, and hypoglycaemia awareness. Participants, investigators, and study teams were not masked to group allocation. Primary endpoint was mean between-group difference in time in range after 6 months assessed in the intention-to-treat sample. This trial is registered with ClinicalTrials.gov, NCT03772600. Between Jan 29 and Jul 30, 2019, 269 participants were recruited, of whom 254 were randomly assigned to rtCGM (n=127) or isCGM (n=127); 124 and 122 participants completed the study, respectively. After 6 months, time in range was higher with rtCGM than with isCGM (59·6% vs 51·9%; mean difference 6·85 percentage points [95% CI 4·36–9·34]; p<0·0001). After 6 months HbA1c was lower (7·1% vs 7·4%; p<0·0001), as was time <3·0 mmol/L (0·47% vs 0·84%; p=0·0070), and Hypoglycaemia Fear Survey version II worry subscale score (15·4 vs 18·0; p=0·0071). Fewer participants on rtCGM experienced severe hypoglycaemia (n=3 vs n=13; p=0·0082). Skin reaction was more frequently observed with isCGM and bleeding after sensor insertion was more frequently reported by rtCGM users. In an unselected adult type 1 diabetes population, switching from isCGM to rtCGM significantly improved time in range after 6 months of treatment, implying that clinicians should consider rtCGM instead of isCGM to improve the health and quality of life of people with type 1 diabetes. Dexcom.